摘要
目的:研究组织培养药敏法在表浅膀胱癌个体化化疗中的意义。方法:用组织培养药敏法检测药物敏感性,选择一种最敏感药物对39例表浅膀胱癌患者术后膀胱灌注化疗,与按经验给药的42例表浅膀胱癌患者对比研究,所有患者随访6～24个月。结果:不同化疗药物对不同个体膀胱癌的抑制率差异明显。39例按药敏结果选择最佳化疗药物的表浅膀胱癌患者,8例(20.5%)复发,而按经验给药42例患者,20例(47.6%)复发,复发率前者显著低于后者(P<0.05,χ2检验)。结论:用Hoffman式组织培养药敏法选择最合适的药物对术后膀胱癌进行化疗,可以明显提高表浅膀胱癌术后的治疗效果,实现表浅膀胱癌的个体化膀胱灌注化疗。
Objective： To study the significance of histoculture drug response assay （HDRA） in individual chemotherapy for bladder cancer. Methods：Sensitivity to chemotherapy drug was determined by HDRA, the most optimal drug was used for intravesical chemotherapy of 39 cases with postoperative superficial bladder cancer, and previous 42 cases with postoperative superficial bladder cancer were given intravesical chemotherapy drug by empiricism, then we compared with tumor recurrence of two groups. All of patients had a following-up time for 6-24 months. Results：In different individual patients, the inhibition rate of each drug was obviously discrepant. 39 cases with superficial bladder cancer underwent intravesical chemotherapy by I-IDRA, 8 cases （20.5%） had recurrent tumor, then 20（47.6 %） of 42 cases with intravesical chemotherapy by empiricism had recurrent tumor, the recurrent rate of the former was significantly low than the later（P〈0.05,X^2 test）. Conclusions： HDRA could be used to choose the optimal drug for chemotherapy of postoperative patients with superficial bladder cancer, which could increase the treatment effects obviously, different patients with superficial bladder cancer could be given individual intravesical chemotherapy by HDRA.
出处
《临床泌尿外科杂志》
2008年第11期854-856,共3页
Journal of Clinical Urology
关键词
组织培养药敏法
表浅膀胱癌
个体化化疗
Histoculture drug response assays Superficial bladder cancers Individual chemotherapy
